Search - tctmd.com

Displaying 21 - 40 of 901

Sort: Relevancy | Date

Presentation TCT 2025

EFS in the US is Back! What’s needed for EFS 2.0 to Maintain and Grow the Program?

Presenter: Michael J. Mack

October 28, 2025

Presentation TCT 2025

Clinical Evidence Experience with First Human Use

Presenter: Alexandre Abizaid

October 28, 2025

Presentation TCT 2025

Expanding Labelling Indications: RCT, Well Constructed Registries, or Both

Presenter: Brad Sutton

October 28, 2025

Presentation TCT 2025

Same Setting Hybrid Procedures: Pulse Field Ablation and Left Atrial Appendage Closure

Presenter: Shephal K. Doshi

October 28, 2025

Presentation TCT 2025

Evidence Requirements for New Generation LAAC

Presenter: Jason H. Rogers

October 28, 2025

Presentation TCT 2025

European Transition from Medical Device Director (MDD) to Medical Device Regulation (MDR): Roadmap for the Future of Global AF Studies

Presenter: Philippe PM Garot

October 28, 2025

Presentation TCT 2025

How Data from the AHA and C3TN Registries of Cardiogenic Shock can Improve Care of Patients with Cardiogenic Shock

Presenter: David A. Morrow

October 28, 2025

Presentation TCT 2025

Evaluating Best Practice Adherence and Outcomes in Cardiogenic Shock: The OASIS Study

Presenter: Navin K. Kapur

October 28, 2025

Presentation TCT 2025

Can New Devices be Approved from Single Arm Studies: Use of Real-World Data as an External Control Group or for Propensity Matching or Generating Objective Performance Criteria

Presenter: Daniel Burkhoff

October 28, 2025

Presentation TCT 2025

Is There a Practical Solution for Emergency Consent in USA Shock RCTs?

Presenter: Graham Nichol

October 28, 2025

Presentation TCT 2025

Moving to Randomized SCAI A Shock CAD Phenotype Approval Studies: Barriers & Solutions

Presenter: Mitchell W. Krucoff

October 28, 2025

Presentation TCT 2025

Electrosurgical Tools in Structural Heart Interventions: How to Drive Best Practices, Device Development, and Regulatory Approval

Presenter: Adam B. Greenbaum

October 28, 2025

Presentation TCT 2025

Digital Versus Invasive Assessment of Functional Lesion Significance: Are Clinical Outcomes Studies Needed If the In Vivo Correlations are Great?

Presenter: Bon-Kwon Koo

October 28, 2025

Presentation TCT 2025

How Should Clinicians Interpret Class 2a and 2b Guidelines Recommendations

Presenter: Jacqueline E. Tamis-Holland

October 28, 2025

Presentation TCT 2025

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

Presenter: Gregg W. Stone

October 28, 2025

Presentation TCT 2025

Leverage Artificial Intelligence in Clinical Trials: Opportunities and Challenges

Presenter: Alexandra Popma

October 27, 2025

Presentation TCT 2025

The Challenges of Recurrent Event Models and Multiple Endpoints

Presenter: Daniele Giacoppo

October 27, 2025

Presentation TCT 2025

Estimands: Clarifying What We’re Measuring in Clinical Trials

Presenter: Roseann M. White

October 27, 2025

Presentation TCT 2025

Pragmatic, Adapted, and Augmented Trials: Ready for Regulatory Approval

Presenter: Sreekanth Vemulapalli

October 27, 2025

Presentation TCT 2025

Joint Modelling for Death and Quality of Life: Worthy as a Primary Endpoint

Presenter: John A. Spertus

October 27, 2025

Advertisement

EFS in the US is Back! What’s needed for EFS 2.0 to Maintain and Grow the Program?

Clinical Evidence Experience with First Human Use

Expanding Labelling Indications: RCT, Well Constructed Registries, or Both

Same Setting Hybrid Procedures: Pulse Field Ablation and Left Atrial Appendage Closure

Evidence Requirements for New Generation LAAC

European Transition from Medical Device Director (MDD) to Medical Device Regulation (MDR): Roadmap for the Future of Global AF Studies

How Data from the AHA and C3TN Registries of Cardiogenic Shock can Improve Care of Patients with Cardiogenic Shock

Evaluating Best Practice Adherence and Outcomes in Cardiogenic Shock: The OASIS Study

Can New Devices be Approved from Single Arm Studies: Use of Real-World Data as an External Control Group or for Propensity Matching or Generating Objective Performance Criteria

Is There a Practical Solution for Emergency Consent in USA Shock RCTs?

Moving to Randomized SCAI A Shock CAD Phenotype Approval Studies: Barriers & Solutions

Electrosurgical Tools in Structural Heart Interventions: How to Drive Best Practices, Device Development, and Regulatory Approval

Digital Versus Invasive Assessment of Functional Lesion Significance: Are Clinical Outcomes Studies Needed If the In Vivo Correlations are Great?

How Should Clinicians Interpret Class 2a and 2b Guidelines Recommendations

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

Leverage Artificial Intelligence in Clinical Trials: Opportunities and Challenges

The Challenges of Recurrent Event Models and Multiple Endpoints

Estimands: Clarifying What We’re Measuring in Clinical Trials

Pragmatic, Adapted, and Augmented Trials: Ready for Regulatory Approval

Joint Modelling for Death and Quality of Life: Worthy as a Primary Endpoint

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content